world-biomarkers-pharma-biotech-2017-tracks

18 / 28

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 42
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Advances on flow cytometry and new immunophenotypic markers on AML diagnosis, prognosis
determination and overall survival
Amanda Costa
Federal University of Sergipe, Brazil
Even though there has been improvements in the understanding and treatment of acute myeloid leukemia (AML), not much
advances are noted when it comes to outcome and survival. It is still substantial the association of AML to a poor prognosis
followed by low remission and survival rates, where 60‒70% of adult patients reach complete remission, but only about 25%
survive with chances of being cured. Although younger patients show a 5-year survival rate of 62.8%, there is a decrease for
people older than 65 years that hits 4%. AML diagnosis remains challenging, being cytogenetics and molecular biology primary
tools for risk stratification and prognostic determination. Moreover, flow cytometry has recently stood out as a useful tool in
AML diagnosis, classification and treatment evaluation, for being able to characterize heterogeneous populations of blast
cells and analyze multiple parameters simultaneously. Important improvements in flow cytometry instrumentation and new
analytical strategies were obtained, nevertheless, there are still limitations regarding new immunophenotypic markers for AML
diagnosis, highlighting the need of new markers in clinical routines, what would increase its diagnosis and prognosis value,
and also be useful for monitoring minimal residual disease (MRD) and improvement of new targeted therapy. Some research
has been developed around the world to evaluate the efficiency of incorporation of new markers on AML immunophenotypic
panels, which has demonstrated a relevant association with the development of the disease, either for its association to a
decreased survival and poor prognosis, for being a possible therapeutic target or because its effectiveness as marker for MRD.
Biography
Amanda Costa is a Pharmacist, graduated from the Pharmacy School of Federal University of Rio Grande do Norte, Brazil. She has completed her Master’s degree
in Pharmaceutical Sciences from Federal University of Sergipe, Brazil, and is currently pursuing PhD from the same University, in which she teaches Hematology
in the Pharmacy School. She has been serving as an Editorial Board Member of the Journal of Hematology and Serology.
Amanda Costa, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109